Resumption of Linezolid Therapy after Myelotoxicity
Open Access
- 1 September 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (5) , 741-742
- https://doi.org/10.1086/377280
Abstract
SIR—Linezolid is associated with hematologic toxicity, including anemia, thrombocytopenia, and pancytopenia [1, 2]. This toxicity is rapidly reversible with withdrawal of the drug from the therapeutic regimen, but no information exists about the risk of resuming linezolid therapy. I recently had the occasion to readminister linezolid therapy at a reduced dose in the treatment of relapsing methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and no recurrence of hematologic toxicity was seen.Keywords
This publication has 4 references indexed in Scilit:
- Linezolid: The First Oxazolidinone AntimicrobialAnnals of Internal Medicine, 2003
- Endocarditis Caused by Methicillin‐ResistantStaphylococcus aureus:Treatment Failure with LinezolidClinical Infectious Diseases, 2002
- Linezolid‐Induced PancytopeniaClinical Infectious Diseases, 2002
- Linezolid and Reversible MyelosuppressionJAMA, 2001